Companies › Henan Genuine Biotech
4 active drug programs in 6 registered trials: 5 Phase 1, 1 Phase 2; Oncology, Genitourinary, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CL-197 capsules HIV-1 antiretroviral agent | – | Phase 2 | HIV-1 Infection | Dec 2026 |
| GEN-725 EGFR tyrosine kinase inhibitor | EGFR | Phase 1 | Advanced Solid Tumors; Non-Small Cell Lung Cancer | Dec 2026 |
| Dositinib mesylate tablets (90-1408) EGFR inhibitor | EGFR | Phase 1 | Non-Small Cell Lung Cancer | Dec 2027 |
| Ro-0622 Reverse transcriptase inhibitor; Replicase polyprotein 1ab inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLR2A | Phase 1 | Renal Insufficiency | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07001436 | Ro-0622 | Phase 1 | Renal Insufficiency | Genitourinary | Aug 2025 |
| NCT07308782 | CL-197 capsules | Phase 2 | HIV-1 Infection | Infectious disease | Dec 2026 |
| NCT07229898 | GEN-725 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT07362940 | GEN-725 | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Jul 2027 |
| NCT07362940 | GEN-725 | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Jul 2027 |
| NCT07231068 | Dositinib mesylate tablets (90-1408) | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Dec 2027 |
AstraZeneca Shanghai Henlius Biotech Jiangsu Hansoh Pharmaceutical Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Nanjing Sanhome Pharmaceutical Jiangsu Aosaikang Pharmaceutical Jiangsu Alphamab Biopharmaceuticals HC Biopharma ArriVent BioPharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.